Phase 3
Completed N=63
Enhancing Adaptations to Exercise
Source: ClinicalTrials.gov NCT03350906 ↗Enrolled (actual)
63
Serious AEs
0.0%
Results posted
Nov 2023
Primary outcomePrimary: Change in Maximum Workload Muscle Strength — 7.5; 3.1 pounds
◆ Published Evidence
Emerging
17citations · ~4 / year
A Randomized Trial of ω-3 Fatty Acid Supplementation and Circulating Lipoprotein Subclasses in Healthy Older Adults.
Summary
Researchers are trying to understand how chronic inflammation affects muscle function and responses to exercise.They are also trying to determine if suppressing chronic inflammation using omega-3 fatty acids (n3-PUFA) restores skeletal muscle function and exercise responsiveness in older adults.
Linked Publications (2)
-
A Randomized Trial of ω-3 Fatty Acid Supplementation and Circulating Lipoprotein Subclasses in Healthy Older Adults.
-
Metabolomic response to acute resistance exercise in healthy older adults by 1H-NMR.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Maximum Workload Muscle Strength |
7.5; 3.1 | — |
| PRIMARY Body Mass Index (BMI) |
27.1; 26.3; 27.2; 26.3 | — |
| PRIMARY Body Fat |
36.9; 35.8; 36.7; 35.8 | — |
| PRIMARY Lean Body Mass |
46.0; 45.5; 46.1; 45.5 | — |
| SECONDARY C-Reactive Protein (CRP) |
1.7; 1.6; 1.5; 2.2 | — |
| SECONDARY Erythrocyte Sedimentation Rate (ESR) |
7.8; 8.8; 7.5; 10.1 | — |
| SECONDARY Weight |
77.3; 74.5; 77.1; 74.5 | — |
Eligibility Criteria
Inclusion criteria
- Men and women between the ages of 20-35 years
- Men and women between the ages of 65-85 years
Exclusion criteria
- Regular use of omega-3 nutritional supplements
- Diabetes or fasting plasma glucose > or equal to 126 mg/dL
- Anemia (female subjects hemoglobin of 1.5mg/dl)
- Chronic active liver disease (AST>144 IU/L or ALT>165 IU/L)
- Oral warfarin group medications or history of blood clotting disorders.
- international normalized ratio (INR) >2.01.5
- Smoking
- Pregnancy or breastfeeding
- Alcohol consumption greater than 2 glasses/day or other substance abuse
- Untreated or uncontrolled hypothyroidism
- Debilitating chronic disease (at the discretion of the investigators)
- Fish or shellfish allergy
Data sourced from ClinicalTrials.gov (NCT03350906) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.